Atara Biotherapeutics (NASDAQ: ATRA) has developed Ebvallo (tabelecleucel), a novel second-line immunotherapy for Epstein–Barr virus–positive post-transplant lymphoproliferative disease (EBV-PTLD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback